Stemline Therapeutics reports fourth quarter 2017 financial results
Stemline Therapeutics reported a net loss of $21.7 million, or $0.93 per share in the 2017 fourth quarter versus a net loss of $10.0 million, or $0.56 per share, for the same 2016 period. Stemline ended the fourth quarter of 2017 with $66.2 million in cash, and cash equivalents. March 16, 2018